UNIFARCO SpA

Unifarco SpA specializes in dermatological creams and topical treatments. Their portfolio includes products like the Ceramol line, which covers skin hydration, psoriasis care, and pigmentation concerns, as well as Proctocreme for hemorrhoidal relief. They also produce Eupilen, which appears to serve dietary or skin-related purposes. These devices are designed for direct application to the skin or affected areas, addressing common dermatological needs.

Unifarco SpA is based in Italy, which places its medical devices under the jurisdiction of the European Union’s regulatory framework. Since their products are classified as Class I and Class IIa devices, they must comply with EU Medical Device Regulations (MDR) or previous Directives (MDD) to ensure safety, performance, and conformity. The company’s location ensures alignment with EU standards, and their devices are listed in the EU’s eudamed database, which is the official registry for medical devices within the EU.

Unifarco SpA’s medical devices are registered in the eudamed database, the official EU-wide registry for medical devices. This platform is maintained by the European Medicines Agency (EMA) and is used to track devices authorized under EU regulations, ensuring transparency and traceability for healthcare professionals, regulators, and patients. Listing in eudamed confirms compliance with EU requirements for device classification and market surveillance.

Unifarco SpA’s devices fall into Class I and Class IIa categories under EU medical device regulations. Classification depends on factors like the device’s intended use, risk level, and interaction with the body. Class I devices pose minimal risk (e.g., basic creams), while Class IIa devices involve slightly higher risks (e.g., specialized dermatological treatments). This classification determines the regulatory scrutiny and conformity assessment procedures required before authorization, ensuring appropriate safety and performance standards are met.